下北阳光灿烂的日子

China's digital industry revenue tops 20 trillion yuan in H1_我的网站

一 |     (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。    (ECNS) -- China's digital industry generated 20.71 trillion yuan (about $2.86 trillion) in revenue in the first half of the year, up 13.6% year on year, according to data released by the Ministry of Industry and Information Technology (MIIT) on Tuesday.    The growth rate rose by 4.1 percentage points from a year earlier and 0.7 percentage points from the first quarter.        Driven by domestic demand for artificial intelligence and strong exports, sector profitability improved, with total profits reaching 1.79 trillion yuan, up 19.3%. The profit margin climbed to 8.6%.    Digital industries remain concentrated in eastern provinces. Guangdong, Jiangsu, Beijing, Shanghai and Zhejiang were among the top 10 regions, together generating 17.21 trillion yuan, or 83.1% of the national total, and contributing 87% of overall growth.    Central China reported digital industry revenue of 2.86 trillion yuan, up 28.3% year on year, accelerating by 18.7 percentage points from a year earlier and outpacing the national average by 14.7 percentage points. Anhui and Hubei provinces led the growth.    MIIT said 16 national‑level advanced manufacturing clusters have been established in sectors including integrated circuits and AI, cultivating backbone enterprises that drive innovation, industrial upgrading and competitiveness.    (By Tang Yuxian)                    。

Current article:http://www.feizengbubaipeirangnalouchuo.sbs/fcl2frg/20260826/5138.xlsx

Published on:09:13:05